• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TenX Keane Acquisition (Amendment)

    2/7/23 7:48:23 PM ET
    $TENK
    Blank Checks
    Finance
    Get the next $TENK alert in real time by email
    SC 13G/A 1 tenku13gamend.txt TENKU13GAMEND UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TenX Keane Acquisition Corp. (Name of Issuer) Units (Title of Class of Securities) G8708L138 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: _ Rule 13d-1(b) X Rule 13d-1(c) _ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Continued on following pages Page 1 of 4 Pages CUSIP NO. G8708L138 Page 2 of 4 Pages CUSIP No. G8708L138 (1) Names of reporting persons Space Summit Capital LLC (2) Check the appropriate box if a member of a group (a) (see instructions) (b) (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 441,678 (6) Shared voting power 0 (7) Sole dispositive power 441,678 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 441,678 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 6.69% (12) Type of reporting person (see instructions) IA * Based on a total of 6,600,000 shares outstanding of the Issuer per 8K Filed October 18, 2022. Item 1(a). Name of Issuer: TenX Keane Acquisition Corp. (the Issuer). Item 1(b). Address of the Issuer's Principal Executive Offices: 420 Lexington Avenue, Suite 2446, New York NY, 10017 Item 2(a). Name of Person Filing Space Summit Capital LLC (the Reporting Person) Item 2(b). Address of Principal Business Office or, if None, Residence: 15455 Albright Street, Pacific Palisades, CA 90272 Item 2(c). Citizenship: The Reporting Person is a Delaware limited liability company. Item 2(d). Title of Class of Securities: Units (the Shares). CUSIP NO. G8708L138 Page 3 of 4 Pages Item 2(e). CUSIP Number: G8708L138 Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) o A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);Page 5 of 6 pages (j) o Group, in accordance with 240.13d-1(b)(1)(ii)(J) Item 4. Ownership: Item 4(a). Amount Beneficially Owned: As of the date hereof, the Reporting Person may be deemed to be the beneficial owner of 441,678 Shares. Item 4(b). Percent of Class: As of the date hereof, the Reporting Person may be deemed to be the beneficial owner of 6.69% of the total number of Shares outstanding. CUSIP NO. G8708L138 Page 4 of 4 Pages Item 4(c). Number of shares as to which such person has: Space Summit Capital LLC (i) Sole power to vote or direct the vote 441,678 (ii) Shared power to vote or to direct the vote 0 (iii) Sole power to dispose or to direct the disposition of 441,678 (iv) Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of Five Percent or Less of a Class: This Item 5 is not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person: This Item 6 is not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company: This Item 7 is not applicable. Item 8. Identification and Classification of Members of the Group: This Item 8 is not applicable. Item 9. Notice of Dissolution of Group: This Item 9 is not applicable. Item 10. Certification: By signing below the Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: 02/07/2023 Space Summit Capital LLC By: /s/ Keith Fleischmann Keith Fleischmann Managing Member
    Get the next $TENK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TENK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TENK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

      TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) ("TenX"), a publicly traded special purpose acquisition company, was notified by The Nasdaq Stock Market that trading in TenX's securities had been halted for "additional information requested" from the company. The trading halt was imposed following volatility in the trading price and volume of TenX's securities on Wednesday, August 7, 202

      8/9/24 7:30:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance
    • TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

      TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "TenX"), a publicly traded special purpose acquisition company, today announced that on August 2, 2024, at the extraordinary general meeting, its shareholders voted to approve the previously announced business combination with the wholly own

      8/5/24 8:00:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance
    • Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

      Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction    Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J., Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane

      8/5/24 8:00:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance

    $TENK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Dutia Suren G

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:29:05 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 4 filed by Director Holubiak Myron Z

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:28:37 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 4 filed by Chief Medical Officer Czuczman Myron

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:28:05 PM ET
      $TENK
      Blank Checks
      Finance

    $TENK
    SEC Filings

    See more
    • SEC Form 25-NSE filed by TenX Keane Acquisition

      25-NSE - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/13/24 4:33:39 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 10-Q filed by TenX Keane Acquisition

      10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      8/9/24 4:22:23 PM ET
      $TENK
      Blank Checks
      Finance
    • TenX Keane Acquisition filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - TenX Keane Acquisition (0001851484) (Filer)

      8/2/24 8:45:17 PM ET
      $TENK
      Blank Checks
      Finance

    $TENK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by TenX Keane Acquisition

      SC 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/15/24 12:53:48 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by TenX Keane Acquisition (Amendment)

      SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)

      3/7/24 4:06:26 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form SC 13G filed by TenX Keane Acquisition

      SC 13G - TenX Keane Acquisition (0001851484) (Subject)

      2/13/24 8:09:57 PM ET
      $TENK
      Blank Checks
      Finance